Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study

This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.

Inclusion Criteria:

• >/= 18 years-old
• Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
• Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers
• >/= 6 months from the date of CAR-T infusion
• Fluent in English
• Able to attend and participate in in-person testing (Arm I)
• Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)

Exclusion Criteria:

• Concurrent enrollment in a CAR-T therapeutics research study
• Unable to be present for the scheduled testing
• Unable to participate in testing due to severe cognitive or physical limitation
• Actively receiving chemotherapy
• Progressive cancer